Unknown PHASE2 INTERVENTIONAL 1-arm NCT02529878

Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer

A Prospective Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Conditions Gastric Cancer

Interventions S1/Paclitaxel chemotherapy plus Apatinib

Updated 6 times since 2017 Last updated: Jul 23, 2016 Started: Aug 31, 2015 Primary completion: Aug 31, 2016 Completion: Aug 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02529878, this PHASE2 trial focuses on Gastric Cancer and remains ongoing. Sponsored by Jiangsu HengRui Medicine Co., Ltd., it has been updated 6 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Sep 2019 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Sep 2019 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu HengRui Medicine Co., Ltd.
The First Affiliated Hospital of Zhejiang Chinese Medical University

Data source: The First Affiliated Hospital of Zhejiang Chinese Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China